Patent · US Active

Detection and use of antiviral resistance mutations

US8859198B2 · kind B2 · utility

13Cited by

1References

7Claims

0Family size

Assignee

ABL SA · LU

Inventors

Angeline Ingrid Bartholomeusz · Melbourne, AU
Stephen Locarnini · Melbourne, AU
Anna Ayre · Melbourne, AU
Lilly Ka Wai Yuen · Melbourne, AU
Peter William Angus · Melbourne, AU
Joseph Sasadeusz · Melbourne, AU
Paul Desmond · Albert Park, AU
Hans Tillman · Leipzig, DE
Thomas Bock · Mont de Marsan, FR
William Sievert · Sydney, AU
Sharon Lewin · Armadale, AU

Key dates

Filing date	Jun 4, 2007
Grant date	Oct 14, 2014
Priority date	—
Expiry date	Aug 19, 2029

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Q2600/156
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. Vaccines and diagnostic assays are also contemplated herein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.